Palatin (PTN) 'Sitting Pretty' After Valeant/Sprout Deal - Roth Capital

Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $4 price target on Palatin Technologies (NYSE: PTN), citing two major inflection points, which we believe continue to strengthen the BMT thesis:

1) Sprout's flibanserin is the first drug approved for female sexual dysfunction and

2) today's announcement of Valeant's (VRX) $1 billion acquisition of Sprout.

"We believe flibanserin faces selling issues with the Black Box warnings relative to BMT's strong safety profile and data, Pantginis commented. "The partnering/acquisition front for PTN could be quite interesting going forward."

For an analyst ratings summary and ratings history on Palatin Technologies click here. For more ratings news on Palatin Technologies click here.

Shares of Palatin Technologies closed at $0.97 yesterday.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Palo Alto Networks (PANW) PT Raised to $390 at UBS, Neutral Rating Maintained
• Centrus Energy Corp. (LEU) PT Raised to $185 at UBS